IVABRADIN AGAINST BISOPROLOL IN PATIENTS WITH CHRONIC HEART FAILURE AND PRESERVED LEFT VENTRICULAL EJECTION FRACTION


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

In a prospective, randomized trial included 126 patients with chronic heart failure with a left ventricular ejection fraction >50% on a background of arterial hypertension and coronary artery disease, a fixed combination of perindopril/amlodipine was used in all cases, with addition of bisoprolol (n=62) or ivabradine (n=64 ). Assessment of clinical status, exercise tolerance, quality of life, blood level of the N-terminal pro-brain natriuretic peptide, and echocardiography were performed baseline and 12 months after therapy. In contrast to bisoprolol, ivabradine significantly increased the exercise tolerance, improved quality of life, reduced the blood level of the N-terminal pro-brain natriuretic peptide, improved echocardiographic indices of active relaxation and compliance of left ventricle. In comparison with bisoprolol, ivabradine has advantages in the treatment of patients with chronic heart failure with preserved left ventricular ejection fraction on background of arterial hypertension and coronary artery disease.

全文:

受限制的访问

作者简介

S. Kanorsky

FSBEI HE “Kuban State Medical University" of RMH

Email: kanorskysg@mail.ru
MD, Prof., Head of the Department of Therapy № 2 Krasnodar

Yu. Borisenko

FSBEI HE “Kuban State Medical University" of RMH

Department of Therapy № 2 of the Faculty of Advanced Training and Professional Retraining of Specialists Krasnodar

参考

  1. Reddy Y.N., Borlaug B.A. Heart Failure With Preserved Ejection Fraction. Curr. Probl. Cardiol. 2016;41:145-88.
  2. Oren O., Goldberg S. Heart Failure with Preserved Ejection Fraction - Diagnosis and Management. Am. J. Med. Epub ahead of print].
  3. Loop M.S., Van Dyke M.K., Chen L., Brown T.M., Durant R.W., Safford M.M., Levitan E.B. Comparison of length of stay, 30-day mortality, and 30-day readmission rates in medicare patients with heart failure and with reduced versus preserved ejection fraction. Am. J. Cardiol. 2016;118:79-85.
  4. Kapton-Cieslicka A., Tyminska A., Peller M., Balsam P., Ozieranski K., Galas M., Marchel M., Crespo-Leiro M.G., Maggioni A.P., Drozdz J., Filipiak K.J., Opolski G. Diagnosis, clinical course, and 1-year outcome in patients hospitalized for heart failure with preserved ejection fraction (from the polish cohort of the European Society of Cardiology Heart Failure Long-Term Registry). Am. J. Cardiol. 2016;118:535-42.
  5. Goyal P., Almarzooq Z.I., Horn E.M., Karas M.G., Sobol I., Swaminathan R.V., Feldman D.N., Minutello R.M., Singh H.S., Bergman G.W., Wong S.C., Kim L.K. Characteristics of hospitalizations for heart failure with preserved ejection fraction. Am. J. Med. 2016; 129:e15-e26.
  6. Murphy T.M., Waterhouse D.F., James S., Casey C., Fitzgerald E., O'Connell E., Watson C., Gallagher J., Ledwidge M., McDonald K. A comparison of HFrEF vs HFpEF's clinical workload and cost in the first year following hospitalization and enrollment in a disease management program. Int. J. Cardiol. 2017;232:330-35.
  7. Ponikowski P., Voors A.A., Anker S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: he Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016; 37:2129-200.
  8. Kriegel A.J., Gartz M., Afzal M.Z., de Lange W.J., Ralphe J.C., Strande J.L. Molecular Approaches in HFpEF: MicroRNAs and iPSC-Derived Cardiomyocytes. J. Cardiovasc. Transl. Res. 2016. [Epub ahead of print].
  9. Yancy C.W., Jessup M., Bozkurt B., et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. J. Am. Coll. Cardiol. 2016;6:1476-88.
  10. Borer J.S., Tavazzi L. Update on ivabradine for heart failure. Trends Cardiovasc. Med. 2016;26:444-49.
  11. Henri C., O'Meara E., De Denus S., Elzir L., Tardif J.C. Ivabradine for the treatment of chronic heart failure. Expert Rev. Cardiovasc. Ther. 2016;14:553-61.
  12. Pereira-Barreto A.C. Addressing major unmet needs in patients with systolic heart failure: the role of ivabradine. Am. J. Cardiovasc. Drugs. 2016;16:93-101.
  13. Psotka M.A., Teerlink J.R. Ivabradine: role in the chronic heart failure armamentarium. Circulation. 2016;133:2066-75.
  14. Petite S.E., Bishop B.M., Mauro V.F. Role of the funny current inhibitor ivabradine in cardiac pharmacotherapy: a systematic review. Am. J. Ther. 2016;23. [Epub ahead of print].
  15. Канорский С.Г. Частота сердечных сокращений и кардиопротекция: новые данные и перспективы. Кардиология. 2015;8:55-61.
  16. Kosmala W., Holland D.J., Rojek A., Wright L., Przewlocka-Kosmala M., Marwick T.H. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J. Am. Coll. Cardiol. 2013;62:1330-38.
  17. Pal N., Sivaswamy N., Mahmod M., Yavari A., Rudd A., Singh S., Dawson D.K., Francis J.M., Dwight J.S., Watkins H., Neubauer S., Frenneaux M., Ashrafian H. Effect of selective heart rate slowing in heart failure with preserved ejection fraction. Circulation. 2015;132:1719-25.
  18. Paulus W.J., Tschope C., Sanderson J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal let ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur. Heart J. 2007;28:2539-50.
  19. Nagueh S.F., Appleton C.P., Gillebert T.C., Marino P.N., Oh J.K., Smiseth O.A., Waggoner A.D., Flachskampf F.A., Pellikka P.A., Evangelista A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J. Am. Soc. Echocardiogr. 2009;22:107-33.
  20. Hoshida S., Shinoda Y., Ikeoka K., et al. Fluctuation of Dynamic Diastolic Function Relative to Static Cardiac Structure - New Insights Into the Underlying Mechanism of Heart Failure With Preserved Ejection Fraction in Elderly Patients. Circ. J. 2017. [Epub ahead of print].
  21. Kishimoto S., Kajikawa M., Maruhashi T., Iwamoto Y., Matsumoto T., Iwamoto A., Oda N., Matsui S., Hidaka T., Kihara Y., Chayama K., Goto C., Aibara Y., Nakashima A., Noma K., Higashi Y. Endothelial dysfunction and abnormal vascular structure are simultaneously present in patients with heart failure with preserved ejection fraction. Int. J. Cardiol. 2017; 231:181-87.
  22. Pandey A., Khan H., Newman A.B., et al. Arterial Stiffness and Risk of Overall Heart Failure, Heart Failure With Preserved Ejection Fraction, and Heart Failure With Reduced Ejection Fraction: The Health ABC Study (Health, Aging, and Body Composition). Hypertension. 2017;69:267-74.
  23. Komori T., Eguchi K., Saito T., Hoshide S., Kario K. Riser Pattern Is a Novel Predictor of Adverse Events in Heart Failure Patients With Preserved Ejection Fraction. Circ. J. 2017;81:220-26.
  24. DE Vecchis R., Ariano C. Aldosterone receptor antagonists decrease mortality and cardiovascular hospitalizations in chronic heart failure (CHF) with reduced left ventricular ejection fraction(LVEF), but not in CHF with preserved LVEF A meta-analysis of randomized controlled trials. Minerva Cardioangiol. 2016. [Epub ahead of print].
  25. Fukuta H., Goto T., Wakami K., Ohte N. The effect of beta-blockers on mortality in heart failure with preserved ejection fraction: A meta-analysis of observational cohort and randomized controlled studies. Int. J. Cardiol. 2017;228:4-10.
  26. Erdem F.H., Ozturk S., Öztürk S., Erdem A., Ayhan S., Öztürk M., Dönmez І., Baltaci D., Yazici M. The Effects of Ivabradine on Left Ventricular Synchronization and Tei Index in Patients with Systolic Heart Failure. Acta Cardiol. Sin. 2017;33:58-65.
  27. Shah A.M., Claggett B., Sweitzer N.K., Shah S.J., Deswal A., Anand I.S., Fleg J.L., Pitt B., Pfeffer M.A., Solomon S.D. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circ. Heart Fai. 2015;8:1052-58.
  28. Aung S.M., Güler A., Güler Y., et al. Left atrial strain in heart failure with preserved ejection fraction. Herz. 2016. [Epub ahead of print].
  29. Santos A.B., Roca G.Q., Claggett B., Sweitzer N.K., Shah S.J., Anand I.S., Fang J.C., Zile M.R., Pitt B., Solomon S.D., Shah A.M. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circ. Heart Fail. 2016;9:e002763.
  30. Ozturk S., Öztürk S., Erdem F.H., Erdem A., Ayhan S., Dönmez І., Yazici M. The effects of ivabradine on left atrial electromechanical function in patients with systolic heart failure. J. Interv. Card. Electrophysiol. 2016;46:253-58.
  31. Sardana M., Syed A.A., Hashmath Z., Phan T.S., Koppula M.R., Kewan U., Ahmed Z., Chandamuri R., Varakantam S., Shah E., Gorz R., Akers S.R., Chirinos J.A. Beta-Blocker Use Is Associated With Impaired Left Atrial Function in Hypertension. J. Am. Heart Assoc. 2017;6:e005163.
  32. Mukete B.N., Cassidy M., Ferdinand K.C., Le Jemtel T.H. Long-Term Anti-Hypertensive Therapy and Stroke Prevention: A MetaAnalysis. Am. J. Cardiovasc. Drugs. 2015; 15:243-57.
  33. Savarese G., Hage C., Orsini N., et al. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction. Circ. Heart Fail. 2016; 9:e003105.
  34. Kitai T., Tang W.H. Pathophysiologic Insights into Heart Rate Reduction in Heart Failure: Implications in the Use of Beta-Blockers and Ivabradine. Curr. Treat. Options Cardiovasc. Med. 2016;18:13.
  35. Polsinelli V.B., Shah S.J. Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. Expert Opin. Pharmacother. 2017. [Epub ahead of print].

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2017
##common.cookie##